M&A - Lyell Immunopharma, Inc.
Form Type: 8-K/A
Filing Date: 2025-01-10
Corporate Action: Acquisition
Type: Update
Accession Number: 000162828025001065
Filing Summary: On January 10, 2025, Lyell Immunopharma, Inc. filed a Form 8-K/A to amend its initial report dated October 31, 2024, regarding the closing of the acquisition of ImmPACT Bio USA Inc. The acquisition was finalized on October 31, 2024, and this amendment provides the historical audited and unaudited financial statements of ImmPACT, along with pro forma financial information as mandated by Item 9.01 of the initial filing. The audited financials for the fiscal year ending December 31, 2023, and unaudited financials for the nine months ending September 30, 2024, are incorporated as Exhibits. The pro forma financials include combined balance sheets and statements of operations for the applicable periods, demonstrating potential impacts of the acquisition on Lyell’s financials. The information aims to present changes resulting from the acquisition, although it notes that actual results may differ materially from those projected in the pro forma statements.
Document Link: View Document
Additional details:
Financial Statements Audited: Exhibit 99.1: Audited financial statements of ImmPACT as of and for the fiscal year ended December 31, 2023.
Financial Statements Unaudited: Exhibit 99.2: Unaudited financial statements of ImmPACT as of and for the nine months ended September 30, 2024.
Pro Forma Financial Information: Exhibit 99.3: Unaudited pro forma condensed combined balance sheet and statements of operations for the Company.
Merger Agreement: Exhibit 2.1: Agreement and Plan of Merger dated October 24, 2024.
Comments
No comments yet. Be the first to comment!